Navigation Links
BioElectronics Corporation Announces Singapore and Malaysia Sales
Date:8/28/2007

FREDERICK, Md., Aug. 28 /PRNewswire-FirstCall/ -- BioElectronics Corporation, (Pink Sheets: BIEL), announced today that Astonix Life Science, has signed a sales and distribution agreement to provide ActiPatch Therapy to the healthcare market in Singapore. The initial order has been shipped and introduction of ActiPatch to the market has been warmly received.

The interest in the benefits of ActiPatch by the Healthcare providers in Singapore has been strong enough to allow Astonix Life Science to move forward in their plan to increase their distribution territory ahead of schedule. They have recently signed an additional agreement for the healthcare market in Malaysia.

"At Astonix Life Science, we are driven by innovations in life sciences. We are proud to be the distributor of ActiPatch. Being able to offer ActiPatch to these markets is an important healing benefit. We are extremely proud to be associated with BioElectronics and the people behind ActiPatch," said Amelia Chew, Director of Astonix Life Science.

"The enthusiasm shown by Astonix Life Science in introducing ActiPatch to the Singapore healthcare market has generated a reciprocal excitement at BioElectronics. We are looking forward to a strong joint commitment to provide the accelerated healing benefits of ActiPatch to the people of Singapore and Malaysia," said Andrew Whelan, President of BioElectronics Corporation.

About BioElectronics:

BioElectronics Corporation is the maker of ActiPatch(TM). ActiPatch is a drug-free anti-inflammatory patch with an embedded battery operated microchip that delivers weeks of continuous pulsed therapy for a few cents per hour. The unique ActiPatch delivery system, using patented technology, provides a cost- effective, patient friendly method to reduce soft tissue pain and swelling.

For more information visit http://www.bioelectronicscorp.com

Safe Harbor Statement:

This news release contains forward-looking statements related to future growth and earnings opportunities. Such statements are based upon certain assumptions and assessments made by management of both companies in light of current conditions, expected future developments and other factors it believes to be appropriate. Actual results may differ as a result of factors over which the companies have no control.


'/>"/>
SOURCE BioElectronics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Trouble-shooting: Misincorporation or low fidelity
2. Roche Diagnostics Corporation
3. Roche Diagnostics Corporation
4. Promega Corporation: Wisconsins quiet innovator
5. Giuliani will keynote RedPrairie Corporations user conference
6. Madison Development Corporation makes loans to three area companies
7. Corporations and blogging
8. Metavante acquires Florida banking corporation
9. TriMas Corporations Cequent Group Acquires Chem-Chrome, Inc.
10. Speaker announces business members of IT Task Force
11. Doyle announces technology tax credits for Berbee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... ... January 18, 2017 , ... DrugDev customers ... Clinical Ops Executives (Hyatt Regency Miami, January 24-26). DrugDev will join customers including ... issues such as trial performance metrics, patient enrollment diversity, protocol optimization, and global ...
(Date:1/18/2017)... ... January 18, 2017 , ... uBiome, the ... paper by its Science Editor, Dr. Elisabeth Bik, in the December 2016 issue ... Bik joined uBiome in October 2016 from her previous position at Stanford University ...
(Date:1/18/2017)... DIEGO , Jan. 18, 2017 Shareholder ... an investigation into whether the board members of CoLucid ... fiduciary duties in connection with the proposed sale of ... a biopharmaceutical company that develops small molecules for the ... 2017, CoLucid announced it had signed a definitive merger ...
(Date:1/18/2017)... IRVING, Texas , Jan. 18, 2017 /PRNewswire/ ... science, and the Lustgarten Foundation, the largest private ... support a clinical trial evaluating the impact of ... is providing clinical trial enrollment services to identify ... and facilitate communication between treating physicians and study ...
Breaking Biology Technology:
(Date:1/12/2017)... PUNE, India , January 12, 2017 A ... 2015 - 2022," projects that the global biometric technology market is expected to generate ... to 2022. Continue Reading ... ...      (Logo: ...
(Date:1/6/2017)... JOLLA, Calif. , Jan. 6, 2017 /PRNewswire/ ... 1 safety studies in healthy volunteers of a ... intended to treat acute pancreatitis. ... is typically a mild disorder, but can be ... organ failure and sepsis, where extended hospital stays, ...
(Date:1/4/2017)... thousands of attendees at this year,s International Consumer Electronics Show (CES), ... devices and services, will be featuring its new line of ULTRA CONNECT ... special CES Exhibit Suite , the new upper arm and wrist smart ... product platform.  Continue Reading ... ...
Breaking Biology News(10 mins):